John Maraganore
Officer, Director at Alnylam Pharmaceuticals, Inc. (ALNY)
John Maraganore has filed 29 insider reports with the SEC since February 2021, as director at Takeda Pharmaceutical Co Ltd (TAK), director at Kymera Therapeutics, Inc. (KYMR) and director at Rapport Therapeutics, Inc. (RAPP) and at 4 more companies. John Maraganore made no open-market purchases or sales in the last 12 months. The latest filing, on July 6, 2026, reports grant or award and sale back to the company at Takeda Pharmaceutical Co Ltd (TAK).
- Filings
- 29
- Companies
- 7
- Bought on market
- None
- Sold on market
- $17.6M
Companies where John Maraganore is an insider
| Company | Role | Shares held | Bought | Sold | Avg buy | Price now | Last filing |
|---|---|---|---|---|---|---|---|
| Director | 10,400 | $21.77 | Jul 6, 2026 | ||||
| Directorsince January 2022 | $115.31 | Jun 25, 2026 | |||||
| Director | $23.16 | Jun 10, 2026 | |||||
| Directorsince November 2021 | $20.90 | Jun 5, 2026 | |||||
| Directorsince July 2022 | $1.04 | Jul 3, 2023 | |||||
| Director | 28,528 | $27.60 | Feb 3, 2023 | ||||
| Officer, Director | 227,663 | $17.6M | $143.82 | Dec 23, 2021 |
Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.
Every filing
- Jul 10, 2026TAKDirector Maraganore John was granted 3,800 units of Ordinary Shares, increasing direct ownership by 58% to 10,400 units (for withholding tax)Form 4Grant or awardSale back to the company
- Jun 24, 2026KYMRSEC Form 4 filed by Director Maraganore JohnForm 4Grant or award
- Jun 10, 2026RAPPSEC Form 4 filed by Director Maraganore JohnForm 4Grant or award
- Jun 3, 2026BEAMSEC Form 4 filed by Director Maraganore JohnForm 4Grant or award
- Jun 25, 2025KYMRSEC Form 4 filed by Director Maraganore JohnForm 4Grant or award
- Jun 17, 2025RAPPSEC Form 4 filed by Director Maraganore JohnForm 4Grant or award
- Jun 4, 2025BEAMSEC Form 4 filed by Director Maraganore JohnForm 4Grant or award
- Jun 18, 2024KYMRSEC Form 4 filed by Director Maraganore JohnForm 4Grant or award
- Jun 5, 2024BEAMSEC Form 4 filed by Maraganore JohnForm 4Grant or award
- Jun 29, 2023PROKSEC Form 4 filed by Maraganore JohnForm 4Grant or award
- Jun 15, 2023KYMRSEC Form 4 filed by Maraganore JohnForm 4Grant or award
- Jun 6, 2023BEAMSEC Form 4 filed by Maraganore JohnForm 4Grant or award
- Sep 20, 2022AGIOSEC Form 5: Maraganore John gifted 1,500 shares, decreasing direct ownership by 5% to 28,528 unitsForm 5Gift
- Sep 1, 2022BEAMSEC Form 4 filed by Maraganore JohnForm 4Grant or award
- Jul 11, 2022PROKSEC Form 4 filed by Maraganore JohnForm 4Grant or award
- Jul 11, 2022PROKSEC Form 3: New insider Maraganore John claimed no ownership of stock in the companyForm 3New insider
- Jun 21, 2022AGIOSEC Form 4 filed by Maraganore JohnForm 4Grant or award
- May 20, 2022AGIOSEC Form 4: Maraganore John converted options into 1,585 shares, increasing direct ownership by 6% to 30,028 unitsForm 4Exercise or conversion of a derivative
- Jan 18, 2022KYMRSEC Form 4 filed by Maraganore JohnForm 4Grant or award
- Jan 17, 2022KYMRJohn Maraganore became an insiderForm 3New insider
- Dec 22, 2021ALNYSEC Form 4: Maraganore John was granted 14,167 shares and covered exercise/tax liability with 6,636 shares, increasing direct ownership by 3% to 227,663 units (tax liability)Form 4Grant or awardShares withheld for taxes or exercise price
- Dec 10, 2021ALNYSEC Form 4: Maraganore John exercised 5,367 shares at a strike of $74.50, increasing direct ownership by 2% to 220,132 unitsForm 4Exercise or conversion of a derivative
- Nov 12, 2021-$5.83MALNYSEC Form 4: Maraganore John exercised 33,978 shares at a strike of $7.10 and sold $5,827,801 worth of shares (33,978 units at $171.52) as part of a pre-agreed trading planForm 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Nov 5, 2021BEAMSEC Form 4 filed by Maraganore JohnForm 4Grant or award
- Nov 5, 2021BEAMJohn Maraganore became an insiderForm 3New insider
- Aug 13, 2021-$6.79MALNYSEC Form 4: MARAGANORE JOHN sold $6,788,196 worth of Common Stock (33,979 units at $199.78) and exercised 33,979 units of Common Stock at a strike of $7.10Form 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- May 28, 2021AGIOSEC Form 4: MARAGANORE JOHN gifted 3,415 units of Common stock and exercised 1,686 units of Common stock at a strike of $0.00, decreasing direct ownership by 6% to 28,443 unitsForm 4GiftExercise or conversion of a derivative
- Apr 20, 2021ALNYSEC Form 4: MARAGANORE JOHN was granted 16,236 units of Common Stock and disposed of $989,822 worth of Common Stock (7,507 units at $131.85), increasing direct ownership by 4% to 214,765 units (tax withholding)Form 4Grant or awardShares withheld for taxes or exercise price
- Feb 25, 2021-$5.01MALNYSEC Form 4: John Maraganore exercised 33,979 units of Common Stock at a strike of $7.10 and sold $5,005,421 worth of Common Stock (33,979 units at $147.31)Form 4Grant or awardExercise or conversion of a derivativeOpen-market sale10b5-1 plan
Also sits on boards with
Officers and directors who share two or more companies with John Maraganore.
Compare John Maraganore with
- John Maraganore vs Steven M Paul2 shared
- John Maraganore vs Yvonne Greenstreet1 shared
- John Maraganore vs Pyott David E I1 shared
- John Maraganore vs Charles Elliott Sigal1 shared
- John Maraganore vs Amy W Schulman1 shared
- John Maraganore vs Giles Richard Platford1 shared
Other insiders at the same companies
- Yvonne GreenstreetALNY
- Pyott David E IALNY
- Charles Elliott SigalALNY
- Amy W SchulmanALNY
- Giles Richard PlatfordTAK
- Teresa Marie BitettiTAK
- Bruce CulletonPROK
- Third Rock Ventures V, L.P.RAPP
- Bethany J CavanaghBEAM
- Nello MainolfiKYMR
- Cheryl GaultRAPP
- Abraham CeesayRAPP
- Lauren Rusckowski DupreyTAK
- Brian AdamsKYMR
- Andrew Stewart PlumpTAK
- Jeremy G ChadwickKYMR
Questions about John Maraganore
- What is John Maraganore's role at Alnylam Pharmaceuticals, Inc.?
- John Maraganore reports to the SEC as officer and director at Alnylam Pharmaceuticals, Inc. (ALNY), according to the latest filing on December 23, 2021. John Maraganore has also filed as director at Takeda Pharmaceutical Co Ltd (TAK), director at Kymera Therapeutics, Inc. (KYMR), director at Rapport Therapeutics, Inc. (RAPP) and director at Beam Therapeutics Inc. (BEAM).
- How many shares does John Maraganore own?
- After the latest filing that states it, John Maraganore directly owned 10,400 shares of Takeda Pharmaceutical Co Ltd (TAK), 28,528 shares of Agios Pharmaceuticals, Inc. (AGIO) and 227,663 shares of Alnylam Pharmaceuticals, Inc. (ALNY). Shares held through trusts, funds or family members are reported separately and are not counted here.
- Has John Maraganore bought or sold stock recently?
- The most recent open-market sale was on November 12, 2021: sold 33,978 shares of Alnylam Pharmaceuticals, Inc. (ALNY) for $5.83M at an average of $171.52.
- How do I get alerts when John Maraganore files?
- Follow John Maraganore on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.
From SEC Forms 3, 4, 5 and 144 filed by John Maraganore (SEC CIK 0001180432). Totals count each trade once, skipping amendments whose original is on file, from Feb 26, 2021 on. View on SEC EDGAR · Get this as JSON